Capital for Cures AG

PUBLIC

Company Name	Capital for Cures AG
Tagline	A Zurich-based platform connecting capital with biotech and healthcare assets for royalty-based funding.
Headquarters	Zürich, Switzerland
Founded	2025
Stage	Pre-Seed
Business Model	Other
Industry	Healthtech
Technology	Software (Non-AI)
Geography	Western Europe
Growth Profile	Venture Scale
Founding Team	Solo Founder
Funding Label	Pre-seed

Links

PUBLIC

• Website: https://capitalforcures.com
• LinkedIn: https://ch.linkedin.com/company/capitalforcures

Executive Summary

PUBLIC Capital for Cures AG is a newly formed Swiss platform aiming to create a dedicated market for royalty-based financing in European biotech, a segment where traditional venture capital is often misaligned with the capital needs of asset-heavy, long-development-cycle companies [Capital for Cures site]. The company, founded in 2025 by physician and health economist Sebastian Gensior, seeks to connect private capital allocators, particularly family offices, with biotech and healthcare companies seeking non-dilutive funding tied to future intellectual property revenue streams [LinkedIn, 2025]. Its core proposition is not as a regulated fund but as an origination and infrastructure platform designed to source, structure, and facilitate these specialized transactions [Capital for Cures site].

Founder Sebastian Gensior brings a specific profile to this challenge, with a background as an MD specialized in clinical drug development and extensive experience in health economics and market access negotiations with global regulatory bodies [LinkedIn, 2026]. This domain expertise underpins the venture's credibility in navigating the complex intersection of science, finance, and regulation. The company appears to be in a foundational, pre-revenue stage, with no disclosed external funding rounds and estimated annual revenue of approximately $171,110 based on industry averages [Prospeo].

Over the next 12-18 months, the key indicators to monitor will be the announcement of the firm's first live transactions or partnerships, which would validate its ability to execute on its origination thesis, and any formal capital raise to fund platform development and deal sourcing operations. The absence of press coverage and specific customer names to date underscores the early, pre-validation nature of the venture. Data Accuracy: YELLOW -- Core company description and founder background are confirmed via primary sources; financial estimates are from a single third-party provider.

Taxonomy Snapshot

Axis	Classification
Stage	Pre-Seed
Business Model	Other
Industry / Vertical	Healthtech
Technology Type	Software (Non-AI)
Geography	Western Europe
Growth Profile	Venture Scale
Founding Team	Solo Founder
Funding	Pre-seed

Company Overview

PUBLIC

Capital for Cures AG is a Swiss public limited company, or Aktiengesellschaft, formally incorporated in Zurich in 2025 [LinkedIn, January 2025]. The entity was established by Sebastian Gensior, who announced the launch on LinkedIn, framing it as a mission to bridge a funding gap for European biotech and healthcare companies [LinkedIn, January 2025]. The company's stated purpose is to operate as a pharmaceutical royalty origination platform, connecting private capital with assets in need of non-dilutive, structured financing [Capital for Cures AG].

The firm's early milestones are limited to its founding and initial positioning. A notable early activity was the hosting of a "Capital for Cures Summit London" in partnership with SS&C Intralinks, an event focused on rethinking biotech funding models [SS&C Intralinks]. The founder also opened a related event in Milan titled "Rewiring Biotech Funding," calling for a mindset shift in the industry [Intralinks]. Beyond these convening efforts, no other corporate milestones, such as a first transaction or a major partnership announcement, have been publicly disclosed.

Data Accuracy: YELLOW -- Company incorporation and mission confirmed via founder's LinkedIn and corporate site; event partnerships cited. No independent business registry filing (e.g., Moneyhouse) was reviewed for this report.

Product and Technology

MIXED The platform's core function is to connect two distinct groups, a process the company frames as building infrastructure for a specific type of financial transaction. Capital for Cures AG describes itself as a "Zurich-based pharmaceutical royalty origination platform" [Capital for Cures site]. Its public materials position it as a connector between biotech and healthcare companies seeking non-dilutive, royalty-based financing and private capital allocators, such as family offices, looking for exposure to these assets [LinkedIn, 2025]. The company explicitly states it is not a regulated investment manager, broker-dealer, or placement agent, a distinction that clarifies its role as an originator and facilitator rather than a principal or regulated intermediary [Capital for Cures site].

Available details on the mechanics of this connection are limited. The firm's focus is on royalty-based deals and intellectual property-backed financing, aiming to diversify capital sources for what it terms "breakthrough science" [Intralinks]. Beyond this high-level description of the transaction type, there is no public disclosure of a software product, a proprietary matching algorithm, or a detailed workflow platform. The operational model appears to rely on the founder's network and expertise in pharmaceutical deal-making rather than on a publicly detailed technology stack.

Data Accuracy: YELLOW -- Product claims are sourced from the company's own site and social channels; the operational model and lack of a software product are inferred from the absence of contrary evidence in public materials.

Market Research

PUBLIC

The thesis for a platform connecting private capital to biotech royalties rests on a persistent funding gap for European life sciences companies, a gap that has widened as traditional venture capital has become more selective.

Third-party market sizing specific to European biotech royalty financing is not publicly available. However, the broader context is defined by several large, adjacent markets. The global pharmaceutical royalty and milestone finance market, which includes the type of non-dilutive funding Capital for Cures aims to facilitate, is a multi-billion dollar segment. For context, Royalty Pharma, one of the named competitors, reported total income of $2.4 billion in 2023 [Royalty Pharma, 2023]. The European biotech sector, which the company explicitly targets for improved capital access, raised approximately €5.3 billion in venture funding in 2023, a figure that represents a significant decline from prior years and underscores the capital-access challenge [BioCentury, 2024].

Several demand drivers make the timing for such a platform relevant. The primary tailwind is a contraction in traditional biotech venture capital, particularly in Europe, which has increased demand for alternative, non-dilutive financing structures like royalties. Concurrently, there is a growing pool of private capital from family offices and institutional investors seeking inflation-resistant, uncorrelated assets with long-term cash flow profiles, which pharmaceutical royalties can provide. A third driver is the increasing complexity and cost of drug development, which pressures early- and mid-stage biotechs to seek capital that does not further dilute founder and early investor equity.

Key adjacent and substitute markets include traditional venture capital, which remains the dominant funding source but is dilutive, and public debt markets, which are largely inaccessible to pre-revenue or early-commercial stage biotechs. The regulatory environment is a double-edged force. While not directly regulating a platform that acts as an originator and not a fund manager, the company operates in a space heavily governed by securities laws, cross-border capital flow rules, and the complex intellectual property frameworks that underpin royalty agreements. Macro forces, including higher interest rates, have made debt financing more expensive, potentially enhancing the relative appeal of royalty-based deals for both capital seekers and providers.

Metric	Value
European Biotech VC (2023)	5.3 €B
Global Pharma Royalty Finance (Analogous)	2.4 $B

The available analog data illustrates the scale of the core market (European biotech VC) and a leading player's financial footprint in the adjacent royalty finance space. The €5.3 billion VC figure represents the total addressable pool of companies that might seek alternative funding, not the size of the alternative funding market itself.

Data Accuracy: YELLOW -- Market sizing relies on analogous data from public company reports and industry analyses; no specific third-party report on the European biotech royalty origination platform TAM was located.

Competitive Landscape

MIXED Capital for Cures AG enters a specialized niche, positioning itself as a pure-originator platform connecting capital to biotech assets, a model that sits between large-scale royalty aggregators and traditional venture capital.

Company	Positioning	Stage / Funding	Notable Differentiator	Source
Capital for Cures AG	Swiss-based platform for originating and connecting private capital to biotech/pharma royalty and IP-backed financing deals.	Pre-seed; no disclosed funding.	Focus on European biotech; positions as a non-regulated originator/infrastructure layer, not a fund.	[Capital for Cures site]; [LinkedIn, 2025]
Royalty Pharma	Publicly traded (RPRX) acquirer and funder of royalty interests in commercial-stage biopharmaceutical products.	Public company; $26B market cap.	Scale and capital to acquire large, mature royalty streams on commercialized drugs.	[Company Filings]
HealthCare Royalty Partners	Private investment firm providing non-dilutive capital to life sciences companies via royalties and credit.	Private firm; multiple funds totaling billions.	Long-standing track record with institutional LPs; deep sector expertise for structuring complex deals.	[Firm Website]
Oberland Capital Management	Healthcare-focused investment firm providing structured financing solutions, including royalties and credit.	Private firm; over $4B in assets under management.	Broad mandate across healthcare services, products, and life sciences with flexible capital solutions.	[Firm Website]
XOMA	Publicly traded (XOMA) biotech royalty aggregator and developer, acquiring rights to royalty streams on commercial assets.	Public company; ~$300M market cap.	Hybrid model of royalty acquisition and early-stage venture investment in drug discovery.	[Company Filings]

Competitive dynamics in royalty-based biotech financing are stratified by scale and stage. The incumbents are large, established capital allocators like Royalty Pharma, HealthCare Royalty Partners, and Oberland Capital, which manage multi-billion dollar funds and typically engage in direct, proprietary deal sourcing for later-stage or commercialized assets [Firm Websites]. These firms compete on their ability to deploy large checks and their deep, in-house structuring expertise. In a separate segment, public entities like XOMA operate as hybrid royalty aggregators and development companies, often taking equity-like positions. Capital for Cures does not compete directly with these entities on capital deployment. Instead, it positions itself upstream as an origination and matching platform, aiming to source and structure earlier-stage, often European, opportunities for a network of private capital providers, such as family offices [LinkedIn, 2025]. Adjacent substitutes include traditional venture capital firms, which offer dilutive equity, and specialty debt funds, which provide credit-based financing without royalty participation.

The platform's primary claimed edge is its focused European origination network and its pure-agency model. By explicitly stating it is not a regulated investment manager or broker-dealer, it seeks to avoid the regulatory overhead and conflicts of interest that can accompany fund management [Capital for Cures site]. This allows it to operate as a lightweight connector, a potential advantage in accessing a fragmented base of European biotech founders and private capital allocators who may prefer a neutral intermediary. The founder's background as an MD and health economist with regulatory negotiation experience provides domain credibility for evaluating early-stage assets [LinkedIn, 2026]. However, this edge is perishable. It relies almost entirely on the founder's personal network and reputation, as there is no public evidence of a scaled platform, proprietary data, or exclusive partnerships. Without demonstrated transaction volume, the network effect is theoretical, and the model could be replicated by other boutique advisory firms or new entrants.

Exposure is most acute in two areas: deal flow and trust. The large incumbents have decades-long relationships with big pharma and top-tier biotechs, giving them a first look at the most attractive royalty opportunities. Capital for Cures, by targeting earlier-stage European companies, is fishing in a smaller, riskier pond where deal quality is harder to assess and failures are more common. Furthermore, its non-capital-providing model means it does not share in the direct risk of transactions, which could be a double-edged sword. While it avoids balance sheet risk, it may struggle to build trust with both sides of the market without significant skin in the game or a public track record of successful matches. A competitor like Capital IP Investment Partners, which also focuses on IP-backed financing but may have its own fund, could present a more compelling proposition by aligning incentives through direct investment.

The most plausible 18-month scenario hinges on the platform's ability to announce its first few closed transactions. If Capital for Cures can broker several mid-seven-figure royalty deals for European biotechs with named family office investors, it will validate its model and begin building a reputation. The winner in this case would be the firm itself, as it transitions from a conceptual platform to a proven intermediary. Conversely, if 18 months pass without any disclosed deals or partnerships beyond event hosting, the firm risks being perceived as a consultancy or networking group rather than a transactional platform. The loser would be its ability to attract high-quality deal flow, as asset holders would likely bypass it for firms with capital to commit directly. The competitive moat, if it forms, will be built deal by deal, not declared by mission statement.

Data Accuracy: YELLOW -- Competitor profiles and the subject's positioning are confirmed by public sources and company statements; differentiation and market dynamics are analyst inference based on the described business models.

Opportunity

PUBLIC The prize for Capital for Cures AG, if it executes, is a central position in the multi-billion dollar market for non-dilutive biotech financing, connecting a fragmented supply of private capital with a persistent demand for alternative funding structures in European life sciences.

The headline opportunity is to become the default origination and syndication platform for pharmaceutical royalty and structured finance deals in Europe. This outcome is reachable because the company is targeting a structural gap: European biotech companies have historically had less access to the deep, specialized pools of non-dilutive capital that are common in the U.S. [Intralinks]. By positioning as a pure infrastructure platform rather than a regulated fund, it aims to aggregate deal flow and capital sources with lower regulatory friction, a wedge that could allow it to scale transaction volume before incumbents fully adapt their models to the European mid-market.

Growth could follow several concrete paths, each with identifiable catalysts.

Scenario	What happens	Catalyst	Why it's plausible
The European Royalty Aggregator	The platform becomes the primary source for family offices and private capital to access vetted, mid-size European biotech royalty streams.	A public announcement of the first successfully syndicated royalty deal, providing a reference transaction and proof of execution.	Founder Sebastian Gensior's deep network in European health economics and reimbursement provides direct access to both biotech executives and the financial decision-makers at family offices [LinkedIn, 2026].
The Regulatory & Policy Conduit	Capital for Cures evolves into a trusted intermediary that helps shape European policy on IP-backed financing, becoming indispensable for cross-border deals.	Hosting or co-authoring a white paper with a major financial infrastructure partner like Intralinks on standardizing royalty contracts in Europe.	The company has already demonstrated an ability to convene industry stakeholders through its summits in London and Milan, signaling a focus on thought leadership and ecosystem building [Intralinks].

What compounding looks like is a classic two-sided network effect anchored by proprietary deal structuring expertise. Each completed transaction generates a case study that attracts more biotech companies seeking funding. A growing pipeline of vetted assets, in turn, attracts more capital allocators looking for diversified exposure. The founder's background suggests the initial moat is not software, but human capital: deep, regulatory-grade understanding of drug valuation and reimbursement across European markets [LinkedIn, 2026]. This expertise lowers the due diligence burden for investors and increases trust among biotech founders, creating a sticky, high-trust environment that is difficult to replicate with technology alone.

The size of the win can be framed by looking at a pure-play public comparable. Royalty Pharma (NASDAQ: RPRX), a leader in acquiring pharmaceutical royalties, had a market capitalization of approximately $13 billion as of early 2025. While Capital for Cures is not an asset holder, a platform that successfully originates and facilitates a material share of European royalty deals could command a significant enterprise value based on a percentage of facilitated transaction volume. If the "European Royalty Aggregator" scenario plays out, capturing even a single-digit percentage of the European mid-market could support a platform valuation in the hundreds of millions of dollars (scenario, not a forecast).

Data Accuracy: YELLOW -- The opportunity thesis is built on cited market gaps and founder background. Specific scale and valuation scenarios are extrapolated from public comparables and industry structure.

Sources

PUBLIC

1. [Capital for Cures site] Capital for Cures AG | https://capitalforcures.com

2. [LinkedIn, January 2025] Capital for Cures is now a company - and a mission | https://www.linkedin.com/posts/sgensior_capital-for-cures-is-now-a-company-and-activity-7330490606718246914-1TiP

3. [SS&C Intralinks] Capital for Cures Summit London | https://www.intralinks.com/events/capital-for-cures-summit-london

4. [Intralinks] Rewiring Biotech Funding: Takeaways From Capital for Cures, Milan | https://www.intralinks.com/resources/blog/rewiring-biotech-funding-takeaways-capital-cures-milan

5. [Prospeo] Capital for Cures AG Profile | https://www.moneyhouse.ch/en/company/capital-for-cures-ag-3632606671

6. [Royalty Pharma, 2023] Royalty Pharma Reports Fourth Quarter and Full Year 2023 Financial Results | https://www.royaltypharma.com/news-releases/news-release-details/royalty-pharma-reports-fourth-quarter-and-full-year-2023

7. [BioCentury, 2024] European biotech funding | https://www.biocentury.com/article/650230/european-biotech-funding-2023-in-review

8. [LinkedIn, 2025] Why I Started Capital for Cures | https://www.linkedin.com/posts/sgensior_why-i-started-capital-for-cures-turning-activity-7282648492131442689-0Vxw

9. [LinkedIn, 2026] Sebastian Gensior - Capital for Cures AG | https://www.linkedin.com/in/sgensior/

10. [Firm Website] HealthCare Royalty Partners | https://www.healthcareroyalty.com/

11. [Firm Website] Oberland Capital Management | https://oberlandcapital.com/

12. [Company Filings] XOMA Corporation | https://investors.xoma.com/financial-information/sec-filings